Merck said on Monday it would split its business into two, creating ⁠a division for its cancer franchise while grouping its ​non-oncology treatments separately.

MRK, is presenting new long term data on its GARDASIL 9 and GARDASIL HPV vaccines at a major international HPV congress. The ...

In the latest close session, Merck (MRK) was down 1.18% at $114.50. This move was narrower than the S&P 500's daily loss of 1.36%. Elsewhere, the Dow saw a downswing of 1.64%, while the tech-heavy ...

Merck MRK is focusing on driving long-term growth through the newer products and a promising set of pipelines as its ...

Merck (MRK) stock is in focus as the FDA approves a label expansion for the company's once-yearly parasiticide treatment.

Merck Marks 10 Years of SPARK™ Merck SPARK™ volunteers bring hands-on science to students worldwide Darmstadt, Germany, March ...

Johnson & Johnson JNJ and Merck MRK are among the top U.S. healthcare giants, making them ideal candidates for a direct ...

Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Value Fund” ...

Oct 7 (Reuters) - Merck (MRK.N), opens new tab is immune from an antitrust lawsuit accusing it of misleading regulators about the effectiveness of its mumps vaccine in order to ward off competition, a ...

We believe that the pharmaceuticals giant Merck (NYSE: MRK) is currently a better pick over its peer, AbbVie stock. MRK stock trades at 14x forward earnings, versus 20x for ABBV. We think this gap in ...

Shares of Merck & Co. Inc. MRK slipped 1.18% to $114.50 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.36% to 6,624.70 ...

Merck reported a 7% year-over-year increase in worldwide sales, totaling $16.1 billion in Q2 2024. The New Jersey-based pharma giant released its latest earnings report on Tuesday morning and ...